6 active not recruiting. 6 Phase 3.
By phase and status
Follow Epcoritamab: new trials by email Literature Review of Epcoritamab trials Research Report on Epcoritamab
Trials (filtered) newest first · largest first
All 6 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Epcoritamab, Rituximab, Lenalidomide - Diffuse Large B-Cell Lymphoma Phase 3 Active not recruiting 379 2024-08-13 2026-04-08
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma Epcoritamab, Prednisone, Rituximab - Follicular Lymphoma (FL) Phase 3 Active not recruiting 1095 2024-02-05 2026-08-04
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Epcoritamab, Cyclophosphamide, Rituximab - Diffuse Large B-Cell Lymphoma Phase 3 Active not recruiting 900 2023-02-08 2026-09-11
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China Epcoritamab, Investigator's Choice Chemotherapy - Diffuse Large B-Cell Lymphoma Phase 3 Active not recruiting 72 2022-10-08 2026-11-10
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma Epcoritamab, Rituximab, Lenalidomide - Follicular Lymphoma (FL) Phase 3 Active not recruiting 549 2022-09-20 2026-07-08
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Epcoritamab, Investigator's Choice Chemotherapy - Diffuse Large B-cell Lymphoma Phase 3 Active not recruiting 483 2021-01-13 2026-11-03
Conditions studied Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Non-Hodgkin (3) · Neoplasms (3) · Lymphoma (2) · Lymphoma, Follicular (2) · Recurrence (1)
Sponsors Genmab (6)
Countries Australia (5) · Belgium (5) · Canada (5) · China (5) · France (5) · Hungary (5) · Japan (5) · Netherlands (5) · Poland (5) · South Korea (5) · Taiwan (5) · Turkey (Türkiye) (5) · United Kingdom (5) · United States (5) · Brazil (4)
Results publications PMID 41371238
NIH funding 2023 (4)